CN109985179A - 一种治疗口腔溃疡的组合物及其制备方法 - Google Patents
一种治疗口腔溃疡的组合物及其制备方法 Download PDFInfo
- Publication number
- CN109985179A CN109985179A CN201910311860.XA CN201910311860A CN109985179A CN 109985179 A CN109985179 A CN 109985179A CN 201910311860 A CN201910311860 A CN 201910311860A CN 109985179 A CN109985179 A CN 109985179A
- Authority
- CN
- China
- Prior art keywords
- parts
- canker sore
- composition
- asparagus
- sore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000020670 canker sore Diseases 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title description 8
- 235000005340 Asparagus officinalis Nutrition 0.000 claims abstract description 35
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 14
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 14
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 13
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 12
- 241000234427 Asparagus Species 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- -1 electuary Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 20
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000000306 recurrent effect Effects 0.000 abstract description 6
- 206010028034 Mouth ulceration Diseases 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 244000003416 Asparagus officinalis Species 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 description 38
- 231100000397 ulcer Toxicity 0.000 description 35
- 210000000214 mouth Anatomy 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 230000036407 pain Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000035876 healing Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 208000002399 aphthous stomatitis Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000004400 mucous membrane Anatomy 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 4
- 241001062009 Indigofera Species 0.000 description 4
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940097275 indigo Drugs 0.000 description 4
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 4
- CRDNMYFJWFXOCH-UHFFFAOYSA-N indirubin Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001584 soft palate Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 240000003824 Gypsophila paniculata Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000382362 Persicaria tinctoria Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- XNPAKGMQCVYQAO-UHFFFAOYSA-N [F].CC(O)=O Chemical compound [F].CC(O)=O XNPAKGMQCVYQAO-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- KNZADIMHVBBPOA-UHFFFAOYSA-N dyclonine hydrochloride Chemical compound [Cl-].C1=CC(OCCCC)=CC=C1C(=O)CC[NH+]1CCCCC1 KNZADIMHVBBPOA-UHFFFAOYSA-N 0.000 description 1
- 229960003462 dyclonine hydrochloride Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- LWYXLXAMDLNBFQ-UHFFFAOYSA-N iso-6-Carnavalin Natural products CC(O)CCCCCCCCCCC1CCC(O)C(C)N1 LWYXLXAMDLNBFQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于药学和食品领域,具体为一种治疗口腔溃疡的新组合物。该组合物包括以下重量份的原料:新鲜芦笋1000‑15000份、唾液乳杆菌0.1‑10份、乳双歧杆菌0.1‑20份、副干酪乳杆菌0.1‑20份、青黛0.1‑50份、淀粉10‑1000份。该组合物应用于复发性口腔溃疡、疱疹性口腔溃疡,可以有效调节机体免疫系统,快速缓解口腔溃疡导致的灼烧疼痛感,具有明显清热敛疮的作用,能够有效治疗口腔溃疡。
Description
技术领域
本发明属于医药与食品技术领域,具体为一种治疗口腔溃疡的组合物及其制备方法。
技术背景
口腔溃疡就是我们平时所说的口疮,口腔溃疡指的就是发生在口腔黏膜的溃疡性损伤性病症,本病分型颇多,可依形态大小、溃疡多少、溃疡深浅分型,尚无统一分型。从临床实用观点出发,将复发性口腔溃疡分3型,多采用世界公认的Lehner分型方法,即分为轻型、重型及疱疹样口炎:
1.轻型溃疡,最常见,约占80%。溃疡不大,一般直径2~4mm。圆或椭圆形,周界清晰,孤立散在,数目不多,每次发作1~5个。好发于角化程度较差的区域,如唇、颊黏膜。角化程度高的龈、腭部较少发生。发作时溃疡有“凹、红、黄、痛”特征。即溃疡中央凹陷,基底不硬,周边围有约1mm的充血红晕带,表面覆有浅黄色假膜,灼痛感明显。复发有规律,一般分为发作期、愈合期和间歇期。发作期又细分为前驱期和溃疡期。前驱期有黏膜局部不适,触痛或灼痛感;约24h后出现白色或红色丘疹状小点;2~3天后上皮破损。进入溃疡期;再经4~5天后红晕消失,溃疡愈合,不留瘢痕。整个发作期一般持续1~2周,具有不治而愈的自限性。间歇期长短不一。因人而异。但一般初发间歇期较长,此后逐渐缩短。直至此起彼伏连绵不断。因刺激痛影响语言、进食、心情,从而对生活质量产生不利影响。
2.疱疹样溃疡。溃疡小而多,散在分布于黏膜任何部位,直径小于2mm,可达数十个之多,似有“满天星”感觉。邻近溃疡可融合成片,黏膜充血发红,疼痛较重。唾液分泌增加,可伴头痛、低热、全身不适、局部淋巴结肿大等症状。发作规律同轻型溃疡,不留瘢痕。
3.重型溃疡,又称复发性坏死性黏膜腺周围炎。腺周口疮溃疡1~2个,大而深,直径可达1~3cm,深可达黏膜下层甚至达肌层,溃疡四周组织红肿,边缘略隆起,触诊较硬,溃疡有灰白色假膜覆盖,触痛明显,经1至数月愈合,愈后留有明显瘢痕。发生在软腭、软硬腭交界处、腭垂或软腭与咽旁处,可见瘢痕,色白,呈挛缩状,或腭垂缺损而变形。如发生在颊部口角处,因瘢痕挛缩,张口受限。重型口疮虽然溃疡大而深,愈合时间很长,自发痛、激发痛较剧烈,但一般无全身症状。
除了上述三种常见的口腔溃疡,还有一类,就是癌症患者口腔溃疡的。近年我国癌症的发病率呈上升趋势,在对肿瘤的治疗外,往往还需要对癌症相关并发症进行预防及治疗。口腔溃疡作为癌症患者常出现的并发症之一,给患者带来巨大的身心痛苦,其易复发的特性也困扰着许多肿瘤科医生。口腔溃疡看似不严重的病症,却给生活带来极大的不便,影响到患者正常的说话、饮食,而且口腔溃疡的症状就是剧烈疼痛,严重情况下口腔溃疡还会诱发多种疾病,如慢性咽炎、便秘等。现有药物多无法从根本上解决口腔溃疡问题,基本都是局部的消炎、止痛、促进愈合治疗,存在治标不治本、治疗时间长和相当部分人群不适的问题。
口腔溃疡的发生是多种因素综合作用的结果,除了缺乏维生素之外会引起口腔溃疡,还有多种因素都会造成口腔溃疡的发生,如精神紧张、局部创伤、自身免疫力低下、营养不良、食物因素、激素水平改变、微量元素的缺乏等都可能会诱发口腔溃疡的发生,现代医学普遍认为,口腔溃疡首先与免疫有着很密切的关系,有的患者表现为免疫缺陷,有的患者则表现为自身免疫反应;同时严重的口腔溃疡或者是经常性的发生口腔溃疡可能预示着身体存在一些潜在的系统疾病,如十二指溃疡、胃溃疡、局限性肠炎、溃疡性结肠炎、维生素B族吸收障碍症等都可能会导致口腔溃疡的发生。目前口腔溃疡的治疗多采用消炎类药物(如如金霉素、氯己啶药膜,去炎松、醋酸氟羟泼尼松软膏,盐酸氯己定含漱液,西地碘含片等)与止痛类药物(如盐酸达克罗宁液,1%普鲁卡因或2%利多卡因液等)进行局部治疗,然而容易引起抗生素依赖、舌苔变黑,牙齿染色、短期多次复发等副作用,急需一种既针对病因从根本上解决又能有效缓解疼痛难忍外在表现的产品。
发明内容
本发明针对上述问题,提供一种可用于治疗口腔溃疡的组合物。该组合物可使口腔溃疡患者的内在免疫得到调节,使口腔局部环境改善,并可迅速缓解口腔溃疡导致的灼烧疼痛感,标本兼顾;同时,无激素添加,不会产生依赖性,且所用原料多为食品原料,安全性极高,经过大量实验室研究与临床超过200例的实际应用,结果表明,本组合物具有明显的调节免疫与清热敛疮作用,能够有效治疗口腔溃疡,特别是对于癌症患者的口腔溃疡有显著治疗和改善作用。
本发明的另外一个发明目的是提供以上所述组合物的制备方法。
为了实现以上发明目的,本发明的技术方案为:
一种治疗口腔溃疡的组合物,其包括以下重量份的原料:新鲜芦笋1000-15000份、唾液乳杆菌0.1-10份、乳双歧杆菌0.1-20份、副干酪乳杆菌0.1-20份、青黛0.1-50份、淀粉10-1000份。
作为优选,所述治疗口腔溃疡的组合物包括以下重量份的原料:新鲜芦笋15000份、唾液乳杆菌2份、乳双歧杆菌4份、副干酪乳杆菌4份、青黛20份、淀粉120份。
上述治疗口腔溃疡的组合物可单独或加入适当药学可接受载体和/或助剂制备成药学可接受的剂型,药学可接受的剂型为丸剂、散剂、胶囊剂、片剂或冲剂。
上述治疗口腔溃疡的组合物可单独或加入适当食品类可接受载体和/或助剂制备成食品类可接受的剂型;保健食品或食品类可接受的剂型为丸剂、胶囊剂、片剂、冲剂、固体饮料或液体饮料。
采用以上所述的治疗口腔溃疡组合物进一步制备成片剂的方法,包括以下步骤:
1)按比例称取各原料,将新鲜芦笋洗净,晾干表面水分;
2)榨取新鲜芦笋,取得汁液,汁液过100目筛;
3)将步骤2)中得到的汁液减压浓缩得25℃时相对密度为1.10-1.20的清膏;减压浓缩时的温度控制在50℃-60℃,优选55℃。
4)将步骤3)中得到的清膏加淀粉喷雾干燥成浸膏粉;
5)向步骤4)中得到的浸膏粉中加入淀粉、唾液乳杆菌、乳双歧杆菌、副干酪乳杆菌、青黛及适量阿巴斯甜、柠檬酸,混匀;
6)将步骤5)中得到的粉末用95乙醇制粒,干燥,加入硬脂酸镁,混匀,压片包衣即得。
阿巴斯甜、柠檬酸和硬脂酸镁的添加量参考现有技术中片剂的制备。
芦笋
入脾、肾经,滋阴止渴、通淋解毒。
芦笋为百合科植物石刁柏的嫩茎,是一种高档而名贵的蔬菜,在国际市场上享有“蔬菜之王”的美称,芦笋富含多种氨基酸、蛋白质和维生素,其含量均高于一般水果和蔬菜,特别是芦笋中的天冬酰胺和微量元素硒、钼、铬、锰等,具有调节机体代谢,提高身体免疫力的功效,在对高血压、心脏病、白血病、血癌、水肿、膀胱炎等的预防和治疗中,具有很强的抑制作用和药理效应。
有人证实口腔溃疡(RAU)患者的淋巴细胞对PHA和刀豆蛋白(ConA)的反应在溃疡各个阶段都比正常人低下。用胸腺病毒作抗原刺激机体时,RAU患者的刺激反应亦属低下。HIV感染的RAU患者病情往往较重,说明RAU可能与免疫功能低下或免疫缺陷有关。现代医学发现,芦笋中的有效成分芦笋多糖可通过改善人体巨噬细胞免疫活性而调节免疫系统功能,这符合中医治本的理论要求,但目前尚无将芦笋直接用于口腔溃疡治疗的研究。
在国家食品药品监督管理局公布的芦笋胶囊产品有两种,分别为芦笋菠萝蛋白酶胶囊和芦笋胶囊,其中,芦笋菠萝蛋白酶胶囊的药品特性为化学药品,芦笋胶囊的药品特性为中药。专利名称为“芦笋胶囊”,申请号201110428074.1中,以10~50%速溶芦笋粉为原料,添加10~90%的植物油、适量的食用色素,混合后的液体或悬浊液封闭于胶囊壳中而制成的芦笋皂苷、多糖、多酚、黄酮含量分别≥20mg/g、≥10mg/g、≥4mg/g、≥2.6mg/g的软胶囊,每日食用的芦笋胶囊中含有芦笋皂苷达到80mg以上。芦笋胶囊具有益气生津的作用,主要用于癌症的辅助治疗即放、化疗后口干舌燥、食欲不振,全身倦怠癌者。
唾液乳杆菌、乳双歧杆菌、副干酪乳杆菌
食品级原料,能有效改善口腔微生物环境,促进炎性部位愈合。
青黛
咸,寒。归肝经。清热解毒,凉血消斑,泻火定惊。用于温毒发斑,血热吐衄,胸痛咳血,口疮,痄腮,喉痹,小儿惊痫。
青黛为爵床科植物马蓝Baphicacanthus cusia(Nees)Bremek.、蓼科植物蓼蓝Polygonum tinctorium Ait.或十字花科植物菘蓝Isatis indigotica Fort.的叶或茎叶经加工制得的干燥粉末、团块或颗粒。青黛含靛蓝5%~8%、靛玉红0.1%以及靛棕、靛黄、鞣酸、β谷甾醇、蛋白质和大量无机盐。
青黛对于口腔溃疡患者,在服用时,即可立刻起到对溃疡部分粘膜的消溃止痛作用,效果明显。
实验研究表明,慢性粒细白血病患者长期大量服用靛玉红后,机体的细胞免疫功能均能随症情的好转恢复到正常水平,原来体液免疫低下的病人服用靛玉红后亦可恢复正常。还可使慢粒病人血液中CAMP的含量随治疗显效而上升,达缓解期时接近正常。药理作用主要体现在:(1)抗病原微生物作用,青黛(木蓝)醇浸液(0.5g/ml)在体外对炭疽杆菌、肺炎球菌、志贺痢疾杆菌、霍乱弧菌、金黄色葡萄球菌和白色葡萄球菌皆有抑制作用;(2)提高动物单核巨噬细胞系统的吞噬功能。
与现有技术相比,本发明的有益效果为:
(一)、本组合物可有效补充人体所需微量元素,对口腔溃疡患者有内在免疫调节与口腔环境改善的作用,增强机体免疫力效果显著,对促进疮疡愈合有良好的效果。
(二)、该组合物应用于复发性口腔溃疡、疱疹性口腔溃疡,可以有效调节机体免疫系统,能迅速缓解口腔溃疡导致的灼烧疼痛感,具有明显清热敛疮的作用,标本兼顾,从而有效治疗口腔溃疡;特别是对于癌症患者的口腔溃疡有显著治疗和改善作用。
(三)、无激素添加,不会产生依赖性,且所用原料多为食品原料,安全性极高。
具体实施方式
为了使本发明的内容更加便于理解,下面将结合具体实施方式对本发明中所述的工艺做进一步的阐述。但不应将此理解为本发明上述主题的范围仅限于下述实施例。
本申请中所采用的原料均为市售产品;其中唾液乳杆菌、乳双歧杆菌和副干酪乳杆菌均采用市售的菌粉,采用规格均为1500亿/g的菌粉。
实施例1:
一种治疗口腔溃疡的组合物,其包括以下重量份的原料:
鲜芦笋10000份、唾液乳杆菌1份、乳双歧杆菌2份、副干酪乳杆菌2份、淀粉160份。
实施例2:
一种治疗口腔溃疡的组合物,其包括以下重量份的原料:
新鲜芦笋12000份、乳双歧杆菌3份、副干酪乳杆菌3份、青黛25份、淀粉150份。
实施例3:
一种治疗口腔溃疡的组合物,其包括以下重量份的原料:
新鲜芦笋13000份、唾液乳杆菌2份、乳双歧杆菌4份、副干酪乳杆菌4份、青黛20份、淀粉120份。
按照实施例1至3中治疗口腔溃疡的组合物的配方,再按照现有技术将其制备成胶囊剂,共制成1000粒,每粒0.3g。
实施例4:
一种治疗口腔溃疡的片剂的制备方法,包括以下步骤:
按比例称取各药材:鲜芦笋15000g、唾液乳杆菌2g、乳双歧杆菌4g、副干酪乳杆菌4g、青黛20g、淀粉120g。
将新鲜芦笋洗净,晾干后榨取新鲜芦笋,取得汁液,将汁液过100目筛,然后将汁液减压浓缩(控制温度在55℃)成相对密度为1.20(25℃)的清膏,加淀粉喷雾干燥成浸膏粉,再加入唾液乳杆菌、乳双歧杆菌、副干酪乳杆菌、青黛及阿巴斯甜2g、柠檬酸2g,混匀,用95乙醇制粒,干燥,加入糊精20g,硬脂酸镁0.6g,混匀,压600片,每片0.5g即得。片剂制备工艺为现有技术,不赘述。
实验研究与病例
口腔溃疡模型大鼠的药效学研究
1材料与方法
1.1动物、仪器与试药
动物:SPF级SD大鼠,雌性,体质量180~220g,由成都达硕实验动物有限公司提供,动物合格证号为SCXK(川)2014-28。四川生物医药产业技术研究院实验动物房SPF屏障系统,室内温度20~22℃,相对湿度40%~70%,12h明暗交替照明,自由饮水。标准饲料由成都达硕实验动物有限公司提供。
仪器:JA1003A型电子天平(上海精天电子仪器有限公司);JY10001型电子天平(上海良平仪器仪表有限公司);CX21FS1C型生物显微镜(奥林巴斯工业有限公司)。
试药:实施例4制备的片剂(口腔溃疡组合物片剂),本试验剂量按每1kg体质量服用0.1g计算;桂林西瓜霜(桂林三金药业股份有限公司,批号为181205,规格为每片3.5g);冰醋酸(AR,成都长联化工试剂有限公司,批号为20170728,规格为每瓶500mL,含量为99.5%),临用时用氯化钠注射液配成20%醋酸溶液;水合氯醛(AR,成都市科龙化工试剂厂,批号为2016020101,规格为每瓶250g);0.9%氯化钠注射液(昆明南疆制药有限公司,批号为C160210D,规格为每瓶500mL)。
1.2方法
1.2.1模型建立
取SD大鼠60只,实验前置室内适应环境7d,室温20~22℃,标准饲料饲养,自由饮水。于造模前24h禁食,正常饮水,次日将大鼠用水合氯醛(350mg/kg)腹腔注射麻醉,于大鼠口腔右侧颊部黏膜下注射20%醋酸,每只0.05mL,正常对照组大鼠注射等量0.99%氯化钠注射液,24h后即可形成口腔溃疡。
1.2.2试验分组及给药
造模第2天(24h后)除正常对照组外,将造模成功的60只大鼠随机分为5组,即模型对照组、阳性对照组(桂林西瓜霜200mg/kg)及实施例1、实施例2、实施例3组(0.2g/kg)。取相应重量口腔溃疡组合物胶囊剂内容物用5mL纯净水溶解后,灌胃给药(留约0.5mL药液缓慢注入大鼠口腔,使药液与溃疡面充分接触);桂林西瓜霜直接取药粉,给药时将药粉(大鼠剂量的1/4)均匀涂于溃疡面上,剩余药粉(大鼠剂量的3/4)以0.5%羧甲基纤维素钠溶液制备成混悬液后灌胃。模型对照组和正常对照组分别灌胃等量0.5%羧甲基纤维素钠溶液,每天2次,连续5d,末次给药后1h处死动物,肉眼观察溃疡表面愈合情况并分级。
1.2.3评级指标
溃疡表面愈合情况分级:0级,肉眼观察溃疡恢复至正常状态;Ⅰ级,表面无明显假膜;Ⅱ级,溃疡表面有薄层黄白色假膜,周围无水肿;Ⅲ级,溃疡表面假膜较厚,且周围伴有炎性水肿。
1.3统计学处理
采用SPSS 13.0统计学软件处理。以均数±标准差(X±s)表示,行t检验和秩和检验。P<0.05为差异有统计学意义。
2结果
2.1对醋酸致大鼠口腔溃疡愈合级数的影响
经肉眼评价各组动物溃疡愈合级数,阳性对照组(桂林西瓜霜200mg/kg)与实施例3组溃疡愈合程度显著提高,与模型对照组比较有显著性差异(P<0.01);实施例1与实施例2组大鼠口腔黏膜溃疡恢复情况较模型对照组有一定改善,但差异无统计学意义(P>0.05)。详见表2。
表1 口腔黏膜溃疡组织学分级标准
表2 各组大鼠口腔溃疡愈合级数比较
注:正常为0分,Ⅰ级为1~3分,Ⅱ级为4~6分,Ⅲ级为7~9分,Ⅳ级为10~12分;与模型对照组比较,*P<0.01。
3讨论
口腔溃疡(RAU)的主要特征是标实本虚,热壅阴伤,即火热内盛,上攻口舌,热壅血滞、瘀热互结是RAU的重要病理因素,根据中医辨证分为心脾积热型、阴虚火旺型、气血亏虚型。目前,RAU的病因和发病机制仍不清楚,故尚无特效疗法。对于重型RAU,多采用局部注射肾上腺皮质激素治疗,疗效显著,但该方法易造成局部周围组织的损伤,患者对局部注射激素具有恐惧感,易产生心理负担,远程患者复诊困难,应用受局限。采用中草药及其复方制剂治疗复发性口疮,主要是通过改善微循环、补充微量元素或调节机体免疫功能,从而达到治疗目的。此外,临床亦采用中成药与中西医结合治疗复发性口疮,如口服中成药牛黄解毒丸,外用药物如青茶散等。但以上疗法均存在治标不治本、治疗时间长和相当部分人群不适等缺陷。
现代医学认为,口腔溃疡的基本病理过程是炎性反应,细胞因子如肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)等发挥重要作用。在炎性反应中,其中TNF-α主要由单核巨噬细胞合成、分泌,同时又以自分泌和旁分泌的方式激活其他细胞如单核巨噬细胞和中性粒细胞,使其产生并释放大量IL-1、IL-6、IL-8、前列腺素E2(PGE2)等炎性介质,激发炎症的连锁反应,加重机体损伤,在炎性反应中起核心作用。芦笋中的芦笋多糖与青黛中的靛玉红对TNF-α的产生有一定抑制作用,从而减轻了炎症损伤,这可能是治疗口腔溃疡的作用机制之一。
综上所述,口腔溃疡组合物(实施例3)对大鼠口腔溃疡有很好的治疗作用,可以防治口腔溃疡。经组织学检查,口腔溃疡组合物对20%醋酸制作的口腔黏膜溃疡模型有较好的疗效。
病例1
患者,男,32岁,2018年11月20日初诊。主诉:口腔多处溃疡,疼痛难忍3天。自行于药店购买地塞米松膜使用,效果不明显。由于疼痛难忍,影响进食,遂于华西医院门诊就诊。现症:口腔多处溃疡,灼热疼痛,齿龈及口腔黏膜充血,咽痛,口干口臭。西医诊断:轻型口腔溃疡。中医诊断:口疮(胃火上炎)。服用口腔溃疡组合物片剂(采用实施例4中配方和方法制备,0.5g/片),早晚分服,每次2片。并嘱患者清淡饮食,忌食辛辣刺激之物,调节放松心情。二诊:服药3天后患者口腔溃疡明显好转,创面缩小,疼痛减轻,未见新发溃疡,牙龈肿痛及咽痛明显缓解,口腔无异味,口干减轻。随访:一周后患者口腔溃疡痊愈,半年内未见口腔溃疡复发。
病例2
患者,女,58岁,2018年7月5日初诊。主诉:甲状腺癌术后7月余,口腔多处溃疡疼痛加重1周。现病史:患者2017年12月体检发现甲状腺右叶结节,切除术后病理示:局灶癌变为甲状腺微小乳头状癌。术后行放疗1周期,未行化疗,规律复查化验及影像学资料,未见复发及转移。患者自放疗后,口腔溃疡反复发作,自行于药店购买复方氯己定地塞米松膜使用,效果不明显。一周前,患者口腔多处溃疡,疼痛难忍,影响进食及说话,遂于华西医院门诊就诊。
现症:口腔多处溃疡,灼热疼痛,齿龈及口腔黏膜充血,咽痛,口干口臭,口渴饮冷,心烦,无发热,纳少,寐欠安,小便黄,大便秘结,3日未解,舌红苔黄,脉弦数。西医诊断:甲状腺癌术后;口腔溃疡。中医诊断:口疮(胃火上炎)。辨证:胃有积热,热循足阳明经脉上攻。服用口腔溃疡组合物片剂(采用实施例4中配方和方法制备,0.5g/片),早晚分服,每次2片。并嘱患者清淡饮食,忌食辛辣刺激之物,调节放松心情。
二诊:服药1周后患者口腔溃疡明显好转,创面缩小,疼痛减轻,未见新发溃疡,牙龈肿痛及咽痛明显缓解,口腔无异味,口干减轻。
随访:2周后患者口腔溃疡痊愈,半年内未见口腔溃疡复发。
虽然本发明已经通过具体实施方式对其进行了详细阐述,但是,本专业普通技术人员应该明白,在此基础上所做出的未超出权利要求保护范围的任何形式和细节的变化,均属于本发明所要保护的范围。
Claims (8)
1.一种治疗口腔溃疡的组合物,其特征在于包括以下重量份的原料:新鲜芦笋1000-15000份、唾液乳杆菌 0.1-10份、乳双歧杆菌 0.1-20份、副干酪乳杆菌0.1-20份、青黛0.1-50份、淀粉10-1000份。
2.如权利要求1所述治疗口腔溃疡的组合物,其特征在于包括以下重量份的原料:新鲜芦笋15000份 、唾液乳杆菌 2份、乳双歧杆菌 4份、副干酪乳杆菌4份、青黛20份、淀粉120份。
3.如权利要求1或权利要求2所述治疗口腔溃疡的组合物,其特征在于:该组合物单独或加入适当药学可接受载体和/或助剂制备成药学可接受的剂型。
4.如权利要求1或权利要求2所述治疗口腔溃疡的组合物,其特征在于:该组合物单独或加入适当食品类可接受载体和/或助剂制备成食品类可接受的剂型。
5.如权利要求3所述治疗口腔溃疡的组合物,其特征在于:药学可接受的剂型为丸剂、散剂、胶囊剂、片剂或冲剂。
6.如权利要求4所述治疗口腔溃疡的组合物,其特征在于:保健食品或食品类可接受的剂型为丸剂、胶囊剂、片剂、冲剂、固体饮料或液体饮料。
7.采用如权利要求1或权利要求2所述治疗口腔溃疡的组合物进一步制备片剂的方法,其特征在于包括以下步骤:
1)按比例称取各原料,将新鲜芦笋洗净,晾干表面水分;
2)榨取新鲜芦笋,取得汁液,汁液过100目筛;
3)将步骤2)中得到的汁液减压浓缩至25℃时相对密度为1.10-1.20的清膏;
4)将步骤3)中得到的清膏加淀粉喷雾干燥成浸膏粉 ;
5)向步骤4)中得到的浸膏粉中加入唾液乳杆菌、乳双歧杆菌、副干酪乳杆菌、青黛及适量阿巴斯甜、柠檬酸,混匀;
6)将步骤5)中得到的粉末用95乙醇制粒,干燥,加入糊精、硬脂酸镁,混匀,压片即得。
8.如权利要求7所述的方法,其特征在于:步骤3)中减压浓缩的温度控制在50℃-60℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910311860.XA CN109985179A (zh) | 2019-04-18 | 2019-04-18 | 一种治疗口腔溃疡的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910311860.XA CN109985179A (zh) | 2019-04-18 | 2019-04-18 | 一种治疗口腔溃疡的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109985179A true CN109985179A (zh) | 2019-07-09 |
Family
ID=67134923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910311860.XA Pending CN109985179A (zh) | 2019-04-18 | 2019-04-18 | 一种治疗口腔溃疡的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109985179A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344324A (zh) * | 2022-01-12 | 2022-04-15 | 山西大学 | 芦笋多糖在制备抗炎药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107343926A (zh) * | 2017-08-22 | 2017-11-14 | 南充市中心医院 | 一种治疗复发性口腔溃疡的中药组合物 |
-
2019
- 2019-04-18 CN CN201910311860.XA patent/CN109985179A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107343926A (zh) * | 2017-08-22 | 2017-11-14 | 南充市中心医院 | 一种治疗复发性口腔溃疡的中药组合物 |
Non-Patent Citations (1)
Title |
---|
蛇蝎颈肩腰膝神贴: "口腔溃疡反复骚扰,老中医有个妙方!", 《HTTP://BLOG.SINA.COM.CN/U/5113660633》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344324A (zh) * | 2022-01-12 | 2022-04-15 | 山西大学 | 芦笋多糖在制备抗炎药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102204406B1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물 | |
US9072721B2 (en) | Composition for preventing or treating immune-related disease and oxidative-stress-related disease | |
KR101419463B1 (ko) | 간질환 예방 및 치료용 생약 조성물 | |
CN106361993B (zh) | 一种防治胃黏膜损伤的药物组合物及其制备方法 | |
CN106901344A (zh) | 一种缓解胃痛腹痛的组合物及其应用 | |
KR20140017932A (ko) | 탱자 발효물에 의한 비만개선효과물질의 조성 | |
CN117379521A (zh) | 一种治疗幽门螺杆菌的植物细胞酶解提取物的制备方法及其应用 | |
CN109985179A (zh) | 一种治疗口腔溃疡的组合物及其制备方法 | |
CN112641097A (zh) | 一种对胃粘膜损伤有辅助保护作用的组合物及应用 | |
CN110538218A (zh) | 一种应用于治疗乳腺炎的组合物 | |
CN107375509B (zh) | 一种用于提高免疫力的保健食品 | |
WO2018171672A1 (zh) | 一种抗癌药物组合物及其用途 | |
US20220249675A1 (en) | Composition for Preventing, Ameliorating, or Treating Gastritis or peptic Ulcer Comprising Anthocyanin-Negatively Charged Polysaccharide Complex as Active Ingredient | |
CN109349645A (zh) | 益生菌组合物、保健食品及其制备方法和应用 | |
CN106349318B (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
AU2019100737A4 (en) | Anti-Helicobacter Pylori Traditional Chinese Medicine composition and applications | |
CN113769029A (zh) | 一种改善肠道吸收、免疫功能的药食同源本草组合物 | |
WO2013141573A1 (ko) | 수영 에탄올추출물을 포함하는 위장질환 개선용 조성물 | |
CN112755168A (zh) | 一种治疗幽门螺旋杆菌引起的慢性胃炎的中药制剂及其制备方法和应用 | |
KR102054121B1 (ko) | 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 함유하는 위염 및 위궤양 예방 또는 치료용 약학 조성물 | |
KR100578665B1 (ko) | 위장질환 환자를 위한 생약조성물을 함유하는 건강기능식품 | |
CN108851071A (zh) | 沙棘vp营养组合物及其制备方法和应用 | |
KR102223638B1 (ko) | 은 화합물과 착화제를 함유하는 항균 조성물 및 삼칠근 추출물을 유효성분으로 포함하는 혈중 전립선 특이항원 안정화제 | |
KR102511606B1 (ko) | 황련 및 오수유의 복합추출물을 유효성분으로 포함하는 만성 역류성 식도염 예방 또는 치료용 조성물 | |
CN113425713B (zh) | 一种治疗十二指肠溃疡的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190709 |